

## UNITED STATES SEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
09/462,472	01/14/00	MATSUI		Н	0010-1075-0-
_		HM12/0621	7	EXAMINER	
OBLON SPIVAK MCCLELLAND				FRONDA	, C
MAIER & NEUSTADT				ART UNIT	PAPER NUMBER
1755 JEFFER FOURTH FLOC ARLINGTON V	iR	HIGHWAY		1652	06/21/01

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

Application No. **09/462,472** 

Applicant(s)

Matsui et al.

## Office Action Summary

Examiner

Christian L. Fronda

Group Art Unit 1652



Responsive to communication(s) filed on	·
☐ This action is <b>FINAL</b> .	
Since this application is in condition for allowance except for form in accordance with the practice under Ex parte Quayle, 1935 C.D.	
A shortened statutory period for response to this action is set to expis longer, from the mailing date of this communication. Failure to reapplication to become abandoned. (35 U.S.C. § 133). Extensions of 37 CFR 1.136(a).	spond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
☐ Claim(s)	is/are rejected.
Claim(s)	is/are objected to.
	are subject to restriction or election requirement.
Application Papers	
See the attached Notice of Draftsperson's Patent Drawing Re-	
☐ The drawing(s) filed on is/are objected to	o by the Examiner.
☐ The proposed drawing correction, filed on	_ is _approved _disapproved.
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority under	
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the	priority documents have been
received.	
received in Application No. (Series Code/Serial Number	
received in this national stage application from the Inter	
*Certified copies not received:	
Acknowledgement is made of a claim for domestic priority diff	del 33 0.3.c. 3 113(6).
Attachment(s)	
<ul><li>☐ Notice of References Cited, PTO-892</li><li>☐ Information Disclosure Statement(s), PTO-1449, Paper No(s).</li></ul>	
Interview Summary, PTO-413	<del></del>
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	
☐ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON THE F	FOLLOWING PAGES

Application/Control Number: 09/462,472 Page 1

Art Unit: 1652

## DETAILED ACTION

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

- I. Claim 1, drawn to a microorganism belonging to the genus *Escherichia* and having purine nucleoside-producing ability.
- II. Claim 2, drawn to a microorganism belonging to the genus *Escherichia* which has acquired a purine nucleoside-producing ability because of an increase of an activity of an enzyme involved in purine nucleoside biosynthesis
- III. Claim 3, drawn to a microorganism belonging to the genus *Escherichia* which has acquired a purine nucleoside-producing ability because of an increase of an expression amount of a gene for an enzyme involved in purine nucleoside biosynthesis
- IV. Claims 4, 5, and 8, drawn to a microorganism belonging to the genus *Escherichia* which has acquired a purine nucleoside-producing ability because of deregulation of control of an enzyme involved in purine nucleoside biosynthesis
- V. Claims 9 and 10, drawn to a microorganism belonging to the genus *Escherichia* which has acquired a purine nucleoside-producing ability because of blockage of a reaction branching from purine nucleoside biosynthesis and leading to another metabolite.
- VI. Claims 11 and 12, drawn to a microorganism belonging to the genus *Escherichia* which is enhanced in purine nucleoside-producing ability by weakening of incorporation of a purine nucleoside into cells of the microorganism.
- VII. Claim 13, drawn to a method for producing a purine nucleoside by fermentation comprising culturing a microorganism belonging to the genus *Escherichia*.
- 2. The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Applicants' invention is the purine nucleoside producing ability of a microorganism belonging to the genus *Escherichia*. Neuhard et al. teach that *Escherichia coli* has a biosynthetic pathway to produce purine nucleosides (see pp. 445-473). Since Applicants' Inventions do not contribute a special technical feature when viewed over the

Application/Control Number: 09/462,472 Page 2

Art Unit: 1652

prior art, they do not have a single general inventive concept and therefore lack unity of invention.

3. Claims 6 and 7 are generic only to Group III or Group IV. If either Group III or Group IV is selected, then claims 6 and 7 will also be examined.

4. Claim 9 is directed toward the following patentably distinct species of enzymes which are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows: succinyl-adenosine monophosphate synthase, purine nucleoside phosphorylase, adenosine deaminase, inosine-guanosine kinase, guanosine monophosphate reductase, 6-phosphogluconate dehydrase, phosphoglucose isomerase, adenine deaminase, and xanthosine phosphorylase.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each of these enzymes are independent chemical entities and require different literature searches that have different limits, scope, and subject matter.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

- 5. A telephone call was made to Kirstern A. Grueneberg on June 18, 2001, to request an oral election to the above restriction requirement, but did not result in an election being made.
- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).
- 8. Any inquiry concerning this communication or earlier communications from the examiner

Application/Control Number: 09/462,472

Art Unit: 1652

should be directed to Christian L. Fronda whose telephone number is (703)305-1252. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703)308-3804. The fax phone number for this Group is (703)308-0294. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703)308-0196.

**CLF** 

NASHAAT T. NASHED PHD. PRIMARY EXAMINER Page 3